Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 7/20 | 0.37 |
| ▸ | HTR2B | P41595 | 4/20 | 0.37 |
| ▸ | HTR2A | P28223 | 2/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | PIM1 | P11309 | 4/20 | 0.32 |
| ▸ | PIM2 | Q9P1W9 | 4/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4475156 | 0.79 | PTGER3 (0.33) | — | |
| SCHEMBL5611262 | 0.73 | NCF1 (0.46) | HTR2CHTR2A | |
| SCHEMBL1737562 | 0.73 | NCF1 (0.46) | HTR2CHTR2A | |
| SCHEMBL4732267 | 0.73 | NCF1 (0.46) | HTR2CHTR2A | |
| SCHEMBL1740973 | 0.73 | HTR1A (0.47) | HTR2CHTR2ASIGMAR1PIM1PIM2 | |
| SCHEMBL1737774 | 0.71 | ROCK2 (0.38) | HTR2CHTR2BHTR2ASIGMAR1 | |
| SCHEMBL4474160 | 0.71 | CHRNA7 (0.39) | HTR2CHTR2ATSHR | |
| SCHEMBL7649513 | 0.71 | PIM1 (0.42) | HTR2CHTR2BHTR2ASIGMAR1HDAC1 | |
| SCHEMBL7649520 | 0.71 | PIM1 (0.42) | HTR2CHTR2BHTR2ASIGMAR1HDAC1 | |
| SCHEMBL7649510 | 0.71 | PIM1 (0.42) | HTR2CHTR2BHTR2ASIGMAR1HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7479559-B2 | 3-[-2-(Piperazin-1-yl)benzyl]pyrrolidin-2-one derivatives; antidepressants, anxiolytic agents; obsessive compulsive disorder, psychological disorders, phobias; 5-HT1 agonist or antagonists; side effect reduction, in particular cardiac QTc prolongation; hydrogenation | PFIZER INC. (US) | 2009-01-20 | — | — | US | disclosed |
| CN-1934081-A | Novel benayl(idene)-lactam derivatives | PFIZER (US) | 2007-03-21 | — | — | CN | disclosed |
| US-20050245521-A1 | Novel benayl(idene)-lactam derivatives | PFIZER INC. | 2005-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245521-A1 | Novel benayl(idene)-lactam derivatives | HTR1E, HTR1D, HTR1A | HTR2C 13/4885HTR2B 11/4885HTR2A 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.